Oral deferiprone for iron chelation in people with thalassaemia (Q24200309)

3

0 references

David J Roberts

object named as

David J Roberts

6

0 references

Sheila A Fisher

1

object named as

Sheila A Fisher

0 references

author name string

Susan J Brunskill

2

0 references

Onima Chowdhury

4

0 references

Sarah Gooding

Cochrane Database of Systematic Reviews

5

0 references

publication date

21 August 2013

0 references

published in

0 references

cites work

Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Deferiprone, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

A multi-center safety trial of the oral iron chelator deferiprone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

The impact of iron overload and its treatment on quality of life: results from a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Hepatic lipid peroxidation in vivo in rats with chronic iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Survival and disease complications in thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Deferiprone and hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Ocular toxicity of high-dose intravenous desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Results of long-term iron-chelating therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Sensorineural hearing loss in children with thalassemia major in Northern Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Light and shadows in the iron chelation treatment of haematological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Academic freedom in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

21 January 2018

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Prevention of iron loading in transfusion-dependent thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

The toxic effects of desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Introduction to The Olivieri symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

A Randomized Controlled Study Evaluating the Safety and Efficacy of Deferiprone Treatment in Thalassemia Major Patients from Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Prolonged survival in patients with beta-thalassemia major treated with deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Reassessment of the Use of Desferrioxamine B in Iron Overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Continuous subcutaenous administration of deferoxamine in patients with iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Erythropoiesis: Comparison of Cytotoxic Aldehyde Generation in Beta-Thalassemia Patients Chelated with Deferoxamine or Deferiprone (L1) Versus NO Chelation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

High-dose desferrioxamine as a cause of growth failure in thalassemic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004839.PUB3

7 January 2021

10.1002/14651858.CD004839.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

4201133

4201133

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference